



ASAM The Voice of Addiction Medicine
American Society of Addiction Medicine

Medicaid Coverage of Medications for the Treatment of Opioid Use Disorder

In Louisiana between 2008-2012, persons enrolled in substance use treatment programs that prescribed methadone **increased 15.3%**. In 2012 in Louisiana, **11.2%** of persons aged 12 and older who met criteria for having a drug use disorder received treatment^α, which was similar to the national rate.

LOUISIANA

State Benefits at a Glance^β...

Methadone

Louisiana Medicaid does not cover methadone under Fee-For-Service (FFS) plans.

Buprenorphine/Naloxone film (Suboxone[®]), Buprenorphine/Naloxone tablets (generic), Buprenorphine/Naloxone tablets (Zubsolv^{®c}) and Buprenorphine tablets (generic).

Medication Limitations

Louisiana Medicaid covers Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets under FFS plans with the following limitations:

- In order to approve the use of Suboxone for the treatment of opioid use disorder, patients do not need to be enrolled in, or have documented proof of, SUD counseling. Counseling requirements for other forms of buprenorphine were not reported.
- Treatment using Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets is limited to 16mg/day after a 3-month period.
- Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets require prior authorization for use.
- Zubsolv appears on Louisiana Medicaid's Preferred Drug List.
- In most cases, Zubsolv is subject to the same prior authorization requirements as the surveyed buprenorphine products.

Louisiana covers Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets as a pharmacy benefit under FFS plans.

Only Suboxone is listed on Louisiana's preferred drug list for FFS plans.

No information was provided about the use of Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets in accredited physician's offices or organized specialty outpatient treatment program (OTP) settings.



State Benefits at a Glance (continued)...

Injectable Naltrexone (VIVITROL®)

Louisiana Medicaid covers injectable naltrexone (Vivitrol®) under both FFS and Managed Care (MC) plans. No information was provided with respect to SUD* counseling for Vivitrol coverage.

- Vivitrol is covered as a pharmacy benefit under FFS plans.
- Vivitrol does not appear on Louisiana’s preferred drug list under FFS plans.
- Prior authorization is required to use Vivitrol.

No information was provided about the use of Vivitrol in physician’s offices or OTP settings.

^o Data from SAMHSA’s State and Metro Reports accessed http://www.samhsa.gov/data/States_In_Brief_Reports.aspx

^p Data as of spring 2014.

^c Zubsolv was not included in the original survey, as the medication was not FDA approved until fall of 2013. This summary reflects only information related to Preferred Drug List (PDL) and formulary inclusion obtained from pharmacy and State websites.

Medicaid Benefits for Treatment of Opioid Dependence Nationwide

Number of Medications Covered under Fee-For-Service Medicaid Plans By State

